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Venous invasion (VI) is a well-established independent prognostic indicator in colorectal can-
cer (CRC). Its accurate detection is particularly important in stage II CRC as it may influence
the decision to administer adjuvant therapy. The Royal College of Pathologists (RCPath) of
the United Kingdom state that VI should be detected in at least 30% of CRC resection
specimens. However, our experience in Ontario, Canada suggests that this (conservative)
benchmark is rarely met. This article highlights the “Ontario experience” with respect to
VI reporting and the key role that careful morphologic assessment, elastin staining and
knowledge transfer has played in improving VI detection provincially and beyond.
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INTRODUCTION
Venous invasion (VI) is a well-established independent predictor
of hematogenous spread and mortality in colorectal cancer (CRC)
(1–8). Although the prognostic importance of VI has been recog-
nized since the late 1930s (1, 9), its assessment remains one of the
most poorly performed aspects of colorectal pathology reporting.
Indeed it is surprising that many of the “giants” in the field that
authored the early papers on colorectal carcinoma, and introduced
the classification of colorectal carcinoma that forms the basis of
the TNM classification, chose to use lymph node metastasis as a
surrogate marker of the risk of metastatic disease rather than VI, a
more direct measure. Unless tumor spreads via the lymphatics and
thoracic duct, it needs to get into veins to disseminate, especially to
the liver. Had they thought this way, the subject of this review may
well have been completely obsolete, and the surprise (and power
of “tradition”) is that it has taken us another 80 years to rethink
what we do and how we do it, as reflected in this review.
Extramural venous invasion (EMVI) is a strong predictor of
adverse outcome (4, 6, 10–14), while the prognostic significance
of intramural venous invasion (IMVI) remains unclear. Several
studies suggest that IMVI may impact outcome, albeit to a lesser
degree than EMVI (6, 10, 15).
Venous invasion is of particular importance in stage II CRC
as its detection may prompt oncologists to consider adjuvant
chemotherapy. The importance of accurate risk stratification in
stage II CRC will become increasingly relevant as the proportion
of node-negative CRC is set to increase with the expansion of
screening colonoscopy programs. Current evidence suggests that
at least 70% of screening detected CRCs are node negative (16).
Thus, the interest in measures other than nodal status to stratify
risk of disease progression in CRC is likely to grow.
The importance of VI is recognized by the UK Royal College
of Pathologists (RCPath), which has recently adjusted its mini-
mum audit standard of VI detection to 30% in CRC resections
(17). However, data from population-based studies indicate that
this standard is rarely achieved (5, 8, 13, 18) with marked vari-
ability in the reported incidence of VI that ranges from 9 to 90%
(8). Such variability is most likely to be attributed to differences in
case mix, reporting criteria, sampling, use of special stains, and the
diligence and skill of the reporting pathologist. Under-reporting
of VI is particularly common outside of sub-specialist units (7, 10,
18, 19).
Accurate detection of VI can be challenging on routine H&E
slides, especially when the muscular wall of the vein is obliter-
ated beyond morphologic recognition or altered by pre-operative
radiation (Figures 1G,H). In these circumstances,VI is easily over-
looked unless key morphologic clues are sought. These include the
so-called “orphan arteriole” sign (a circumscribed tumor nodule
adjacent to muscularized artery without an obvious accompany-
ing vein) (Figures 1A,B) and the “protruding tongue sign” (a
smooth bordered protrusion of tumor into pericolic fat adja-
cent to an artery) (Figure 1E). Either of these findings, in the
absence of a clearly visualized vessel wall, should prompt an
elastin stain (Figures 1C,F) and/or a smooth muscle immunos-
tain (Figure 1D), which will resolve the vast majority of equivocal
cases (19, 20).

























































Dawson et al. Venous invasion in colorectal cancer
FIGURE 1 | (A,B) “Orphan arteriole” sign (circumscribed tumor nodule
adjacent to muscularized artery without an obvious accompanying vein).
The residual vessel wall (arrow) can be highlighted with elastin trichrome
stain (C) or immunohistochemical stain for caldesmon (smooth muscle
marker) (D), facilitating the detection of VI. (E) “Protruding tongue sign”
(rounded tongue-like protrusion of tumor into pericolic fat adjacent to an
artery [A]). (F) An elastin stain highlights elastin fibers of the residual
vessel wall which has been partially obliterated by tumor. (G) In some
instances detection of VI can be virtually impossible on (H,E) but easily
recognized on the elastin stain (H).
THE ROLE OF ELASTIN STAINING
There is a growing body of evidence that routine elastin staining
substantially increases VI detection. Many studies have demon-
strated the superiority of elastin staining compared to H&E alone
in the assessment of VI, with the majority reporting a two to
threefold increase in VI detection with elastin stains (15, 19,
21–24).
Furthermore, evidence suggests that VI assessed with an elastin
stain may be a far better predictor of cancer survival than VI
assessed by H&E alone. Roxburgh et al. (15) studied 419 patients
undergoing curative CRC resection (before and after the intro-
duction of routine elastin staining at their institution, n= 194
and 225, respectively) and found elastin-detected VI to be supe-
rior at predicting 3-year cancer-specific survival than VI detected
by H&E alone. A follow-up study of 631 CRC resections found
elastin-detected VI to be associated with a decrease in 5-year
cancer-specific survival from 92 to 67% in node-negative disease
(T1-4,N0) and from 79 to 42% in node positive disease (T1-
4,N1/2). The combination of T-stage and elastin-detected VI was
at least equivalent to T-stage and nodal status in predicting cancer-
specific survival, and superior to TNM in node-negative disease
(14). This led the authors to propose a “TVI” staging system as
a simple alterative to TNM. Suzuki et al. (25), in a study of 124
patients with stage I CRC, found only elastin-detected VI to be
an independent predictor of distant metastasis (VI detected on
H&E alone was not significant on either univariate or multivariate
analysis). Baumhoer et al. (26) failed to demonstrate a difference in
5-year survival between patients with and without elastin-detected
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VI in 185 patients with stage I and II CRC, but the study was limited
by type II error due to the relatively small sample size.
Not surprisingly, the accuracy of VI detection on H&E has been
shown to affect its prognostic power. Betge et al. (10) compared the
prognostic significance of original vs. review diagnoses of VI (the
latter by two experienced GI pathologists) in 381 CRC resection
specimens. Review diagnoses of VI had a much stronger influence
on both progression free survival [HR 3.97 (95% CI 2.71–5.81),
p< 0.001 vs. HR 1.01 (95% CI 0.60–1.71), p= 0.96] and cancer-
specific survival [HR 4.45 (95% CI 2.96–6.68), p< 0.001 vs. HR
1.05 (95% CI 0.60–1.84), p= 0.87] than did diagnoses made in
the routine setting.
THE ONTARIO EXPERIENCE
Institutional and provincial audits in the province of Ontario,
Canada have revealed under-reporting of VI in CRC resections
(18, 27) with a provincial VI detection rate of just 14% in 2010
(11% if academic hospitals were excluded)1. In order to determine
the reasons for such under-reporting, a population-based survey
of 361 Ontario pathologists was undertaken (18). A 15-item sur-
vey addressed reporting criteria (n= 6), the use of special stains
(n= 5), and demographic information (n= 4). Pathologists were
also asked to provide a self-estimate of their VI detection rates
in CRC resection specimens (<10%; 10–19%; 20–29%; >30%).
The overall response rate was 65%, which is relatively high for a
survey of physicians. A majority of pathologists (70.2%) consid-
ered their VI detection rates to be <10%, with only 9% reporting
VI detection rates >20%. Factors independently associated with
estimated VI detection rates of ≥10% included (1) practice in
a university-affiliated center, (2) a sub-specialist interest in GI
pathology, and (3) application of the“orphan artery criterion”(i.e.,
tumor nodule adjacent to an artery where residual smooth muscle
or elastin can be demonstrated on H&E or special stains) (18).
Higher rates of VI detection among GI1 pathologists and those
practicing in university-affiliated centers were also noted in insti-
tutional and provincial audits (18, 27) as well as in a study using a
pre-defined set of cases (19). In the latter, the use of an elastin stain
more than doubled VI detection by both GI and general pathol-
ogists (p= 0.001) and increased interobserver agreement for the
detection of EMVI (H&E: κ= 0.23 vs. Elastin: κ= 0.41) (19).
The under-reporting of VI in Ontario, together with the height-
ened awareness generated by the population-based survey and
the availability of a provincial mailing list presented a unique
opportunity for practice improvement through knowledge trans-
fer. Initially, an educational document was sent to all Ontario
pathologists on the provincial mailing list providing the following
information:
(1) Detailed feedback on the results of the VI survey
(2) Information regarding the prognostic importance of VI and
the RC Path UK minimum standard for VI and
(3) A set of micrographs illustrating both the morphologic clues
for VI detection (i.e., “orphan arteriole” and “protruding
1During this period, provincial reporting was performed according to the College of
American Pathologists checklist (version 6) based on AJCC/UICC TNM 6th edition
which required separate reporting of large vessel (venous) and small vessel invasion.
tongue” signs) and the utility of elastin staining in enhancing
VI detection.
Broader national exposure was achieved by publication of a
similar document in the Journal of Canadian Pathology (28).
The impact of these initiatives is beginning to emerge at an
institutional, provincial and national level. Many institutions in
Ontario have since implemented routine elastin staining on all
CRC resections. At our institution, elastin trichrome stains are per-
formed on a minimum of five tumor-containing blocks per case.
The associated costs are modest (about $3–4 per slide) and there
has been no impact on turn-around time as stains are performed
up front on pre-selected blocks. A recent audit of VI detection
rates at Mount Sinai Hospital for the year prior to and the year
following implementation of routine elastin staining revealed a
twofold increase in VI detection rates (20.0–42.0%) that was inde-
pendent of other clinicopathologic variables [adjusted Odds Ratio,
3.54 (95% confidence interval, 1.89–6.63); p< 0.001]. Compa-
rable VI detection rates were achieved by both gastrointestinal
(GI) and non-gastrointestinal (non-GI) pathologists (41 and 44%,
respectively) (unpublished data).
Similar improvements in VI detection were observed among
Ontario pathologists who had participated in the interobserver
variability study VI in CRC (19, 29). Participants of this study were
invited to submit pathology reports from all CRC resections issued
in the 18 months prior to, and 18 months following completion of
the study. Nine of the 12 pathologists (5 GI, 4 non-GI) submit-
ted reports they had signed out (n= 233 pre-study and n= 216
post-study). Again, a two-fold increase in VI detection rates in the
post-study period was noted [18.5–39.8% overall (p< 0.0001),
18.2–38.4% for GI pathologists (p< 0.001), and 19.1–45.6% for
non-GI pathologists (p< 0.002)]. In addition, the mean number
of elastin stains per case increased from 0.10 (SE, 0.41) to 2.51
(2.06) (p< 0.001), while the mean number of tumor-containing
blocks per case remained constant [8.28 (6.69) vs. 8.12 (4.07);
p= 0.761]. There were no significant differences in small vessel
invasion, TNM stage, tumor location or proportion of patients
receiving neoadjuvant therapy pre- and post-study.
The broader impact of knowledge transfer on VI detection at
a provincial level was addressed by means of a follow-up survey
of pathologists in Ontario. Participants were asked whether or not
they considered their VI detection rates and use of elastin stains
in CRC resections to have increased since the original 2010 VI
practice pattern survey and receipt of the feedback/educational
material that followed. Despite a relatively low response rate of
24%, 33 different hospitals were represented. Overall 67.5% of
respondents considered their use of elastin stains to have increased,
including 85% (11/13) of GI pathologists and 62% (38/61) of non-
GI pathologists. Of those who reported increased use of elastin
stains, 72% (36/50) felt that their VI detection rates had increased;
this included 91% (10/11) of GI pathologists and 67% (26/39)
of non-GI pathologists. Of those who reported no increase in
elastin staining, only 8% (2/26) felt that their VI detection rates
had increased. There was a highly significant association between
the increased use of elastin staining and a perceived increase in VI
detection (p< 0.0001). Finally, unpublished results from a survey
of North American pathologists revealed that 46.5% of Canadian
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GI pathologists (20/43) routinely performed an elastin stain on at
least one tumor-containing block on every CRC resection com-
pared to less than 2% (1/58) of US GI pathologists. Differences
were also seen between Canadian and US non-GI pathologists
[19% (15/79) vs. 2% (3/139), respectively]. It would appear that
knowledge transfer initiatives have influenced pathology practice
with respect to VI reporting at both a provincial and national level
in Canada.
INTERNATIONAL CRITERIA FOR THE REPORTING OF VESSEL
INVASION
Colorectal cancer reporting protocols of the RC Path (UK), Royal
College of Pathologists of Australasia (RCPA), College of Amer-
ican Pathologists (CAP), and Japanese Society of Cancer of the
Colon and Rectum (JSCCR) vary considerably with respect to
blood vessel and lymphatic vessel invasion reporting.
The recently updated RC Path dataset (17) includes only venous
(large vessel) invasion as a mandatory data element (reported as
extramural, intramuscular or submucosal) and regards the evi-
dence as insufficient for mandatory reporting of lymphatic and
small vessel invasion. Talbot’s definition of VI as “tumor present
in an endothelium-lined space surrounding a rim of smooth mus-
cle or containing red blood cells” remains in use, but in addition
the demonstration of a convincing elastic lamina around a tumor
nodule is now considered sufficient to categorize as positive for
VI, even if an endothelial-lined space is not visible. The guidelines
recommend that VI is detected in at least 30% of CRC resections
and that individual centers should monitor VI detection rates and
consider routine elastin staining to facilitate its detection if the
30% minimum standard is not met (Table 1).
The RCPA guidelines (30) recognize the significance of both
large vessel (venous) and small vessel (lymphatic and capillary)
invasion and recommend separate documentation of each as well
as the distinction between EMVI and IMVI. The use of histo-
chemical and immunohistochemical stains is encouraged if there
is a suspicion of VI on H&E.
While the CAP reporting guidelines (31) recognize the supe-
rior prognostic significance of EMVI, all forms of blood vessel and
lymphatic invasion (large and small vessel) are grouped under the
broad term “lymph-vascular invasion.” Currently there are no rec-
ommendations regarding the use of special stains to identify blood
vessel or lymphatic invasion.
Consensus guidelines for the assessment of lymphatic and
blood vessel invasion from the Pathology Working Group of the
JSCCR have recently been developed using the Delphi method
(32). Diagnostic criteria for elastica-detected VI and D2-40-
detected LI include an elastic membrane covering more than half
of the circumference of a tumor cluster even without an accom-
panying artery or vessel structure and D2-40 positive endothelial
cells covering at least half of the circumference of a tumor clus-
ter, respectively. However, a recent international study group found
that attempts to apply these criteria were associated with a decrease
in interobserver agreement (33). JSCCR guidelines suggest the sep-
arate reporting of blood vessel and lymphatic vessel invasion, but
do not distinguish the size of the vessel.
The variation in national/regional pathology reporting guide-
lines for blood and lymphatic vessel invasion may influence patient
Table 1 | Recommendations for the detection ofVI (8, 17).
A minimum of four or five tumor blocks [as included in most sampling
protocols (17)] should be submitted for optimum assessment of VI.
When submitting blocks, areas of linear spiculation at the infiltrating edge
of the tumor should be targeted for histological examination.
In rectal cancers, detection of VI should be guided by MRI findings in
terms of the presence or absence of EMVI. If EMVI is reported present
on imaging, every effort should be made to detect EMVI including
additional sampling, careful histologic examination and elastin stains (if
not already implemented).
Morphological clues play a key role in detecting VI. Particular attention
should be paid to the presence of the orphan arteriole or protruding
tongue signs on H&E. Elastin stains should be performed on all blocks
equivocal for VI.
Individual departments should monitor their VI detection rates with regard
to the UK RC Path minimum audit standard of 30% in all CRC resections.
In departments where this benchmark is not met, routine elastin staining
of most or all tumor blocks should be considered. When ordered at the
time of grossing, this is associated with only minimal additional costs, and
there is no significant increase in turn-around times.
management. While most national guidelines recommend that
adjuvant chemotherapy be offered in “high-risk” stage II dis-
ease (34, 35), precisely what defines “high-risk” in terms of vessel
invasion differs regionally. For instance, the US-based National
Comprehensive Cancer Network considers any type of blood or
lymphatic vessel invasion (34) as a high-risk feature in Stage II
CRC; this is in line with the CAP guidelines grouping of all forms
of blood and lymphatic vessel invasion in single category (“lymph-
vascular invasion”). In contrast, EMVI but not other types of
blood/lymphatic vessel invasion are considered “high-risk” by the
National Institute for Health and Care Excellence in the UK (35)
in line with UK pathology guidelines requiring separate report-
ing of EMVI and which do not include small vessel invasion as a
mandatory data element.
Finally, while current guidelines recommend chemotherapy be
offered in stage II CRC with any “high-risk” feature, the relative
benefit of chemotherapy for individual “high-risk” features (such
as VI) remains to be determined. Attempts to determine the rela-
tive benefit of chemotherapy for VI in stage II CRC are currently
limited by (1) low VI detection rates and lack of central review in
some major trials [e.g., VI rate of 13% in the QUASAR (36) and
8.9% of Stage II patients in the MOSAIC trial (37)], (2) insensitive
methods for VI detection (i.e., H&E stain alone), and (3) relatively
small numbers when subgroup analyses are performed. Therefore
prospective studies to determine the relative benefit of chemother-
apy in patients with elastin-detected VI would be of considerable
interest and importance.
CONCLUSION
Venous invasion, particularly when in an extramural location,
is a powerful prognostic factor in CRC. Its presence in stage II
CRC may prompt oncologists to offer adjuvant chemotherapy.
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Institutional and provincial audits in Ontario identified wide-
spread under-reporting of VI, which led to several knowledge
transfer initiatives in the province. These appear to have had an
impact on the detection and reporting of VI both at a provin-
cial and national level. In particular, recognition of key diagnostic
clues, such as the “orphan artery sign” and “protruding tongue
sign” and use of elastin staining can substantially increase VI
detection rates. In turn, the more accurate/sensitive detection of
VI has been shown to increase its prognostic power. Future chal-
lenges include establishing evidence based internationally accepted
guidelines for the definition and reporting of blood vessel and lym-
phatic invasion, and implementing of methods to improve their
detection.
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